Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis

被引:27
作者
Adler-Moore, JP [1 ]
Olson, JA [1 ]
Proffitt, RT [1 ]
机构
[1] Calif State Polytech Univ Pomona, Dept Biol Sci, Pomona, CA 91768 USA
关键词
AmBisome loading dose; antifungal therapy; intermittent AmBisome dosing;
D O I
10.1093/jac/dkh460
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: This study was done to determine whether high dose AmBisome (4-20 mg/kg), given intermittently, could reduce the frequency of dosing needed to treat murine systemic candidiasis when compared with conventional daily treatment. Methods: Mice were immunosuppressed with cyclophosphamide every 3 days, beginning day -3 before challenge with log(10) 5.0 cfu Candida albicans. Treatment was begun 48-72 h post-challenge with daily or intermittent dose regimens of AmBisome, followed by determination of kidney cfu for up to 1 month post-treatment. Results: A single AmBisome dose of 4 mg/kg was as effective as four daily, 1 mg/kg treatments. A total of 8 mg/kg, given as 4 mg/kg on days 2 and 4, or as 5 mg/kg on day 2 followed by 1 mg/kg on days 3, 4, and 5, also produced comparable efficacy. While 20 mg/kg given day 2, 4 and 6 post-challenge as a 1 week loading dose, followed by one 10 mg/kg treatment on day 13, decreased the fungal burden by up to 5 logs compared with controls (log(10) 2.3 cfu/g and log(10) 7.5 cfu/g, respectively), 20 mg/kg given Monday, Wednesday and Friday for 5 weeks, reduced the fungal burden to undetectable levels (i.e. log(10) 1.0 cfu). Conclusions: Significant reduction or clearance of kidney cfu, following intermittent, high dose AmBisome treatment, indicated that non-daily dosing regimens could be successfully used instead of conventional daily dosing to treat established C. albicans infection in immunosuppressed mice.
引用
收藏
页码:1096 / 1102
页数:7
相关论文
共 32 条
[1]  
Adler-Moore Jill, 2003, Curr Opin Investig Drugs, V4, P179
[2]  
ADLERMOORE J, 1994, BONE MARROW TRANSPL, V14, pS3
[3]  
ALBERT MM, 1995, J MYCOL MED, V5, P1
[4]   PROPHYLACTIC EFFICACY OF AEROSOLIZED LIPOSOMAL (AMBISOME) AND NON-LIPOSOMAL (FUNGIZONE) AMPHOTERICIN-B IN MURINE PULMONARY ASPERGILLOSIS [J].
ALLEN, SD ;
SORENSEN, KN ;
NEJDL, MJ ;
DURRANT, C ;
PROFFIT, RT .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1994, 34 (06) :1001-1013
[5]  
Boswell GW, 1998, ANTIMICROB AGENTS CH, V42, P263
[6]   AmBisome (Liposomal amphotericin B): A comparative review [J].
Boswell, GW ;
Buell, D ;
Bekersky, I .
JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (07) :583-592
[7]   A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients [J].
Bowden, R ;
Chandrasekar, P ;
White, MH ;
Li, X ;
Pietrelli, L ;
Gurwith, M ;
van Burik, JA ;
Laverdiere, M ;
Safrin, S ;
Wingard, JR .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (04) :359-366
[8]  
Buisman AM, 1999, IMMUNOLOGY, V97, P601
[9]   Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits [J].
Clemons, KV ;
Sobel, RA ;
Williams, PL ;
Pappagianis, D ;
Stevens, DA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2420-2426
[10]   The first echinocandin: caspofungin [J].
Cornely, OA ;
Schmitz, K ;
Aisenbrey, S .
MYCOSES, 2002, 45 :56-60